2017 IMPAACT Annual Meeting Tuberculosis Scientific Committee Presentations

Anneke Hesseling

PHOENIx (A5300/IMPAACT 2003): Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design	Amita Gupta
IMPAACT 2001: Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection	Jyoti Mathad
P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease	Anneke Hesseling
IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB	Ethel Weld

SMaRT Kids, the Adult MDR-TB Trials Landscape and Moving Pediatric TB Trials Forward	Tony Garcia-Prats
Emerging Data on Delaminid Pharmacokinetics and Safety in Children with MDR-TB	Jeffrey Hafkin
Using Pharmacokinetic Modelling to Evaluate Novel TB Drugs in Children More Efficiently: Experiences from BDQ CRUSH, P1108 and IMPAACT 2005	Elin Svensson
Update on Phenotypic and NGS-based Advances for Drug Susceptibility Testing and Their Use in Context of Clinical Trials	Marco Schito
Quantification of Circulating Mtb Antigen Peptides for Rapid Diagnosis and Treatment Monitoring	Tony Hu
Novel Blood-based Biomarkers for Pediatric TB	Jeff Tornheim Mandar Paradkar